. The function of SK-S1P in cancer is complex and is influenced by cell type, receptor expression, subcellular localization and environmental context. In this Review, we discuss the evidence that S1P, S1P receptors, SK, S1P phosphatases and SGPL1 are involved in cancer and chemotherapeutic resistance. We examine these findings with the knowledge that both ceramide and sphingosine are associated with the induction of apoptosis (the ceramide-sphingosine-S1P rheostat model), and that S1P binds to GPCRs and/or undefined intracellular targets to regulate cancer growth, survival and motility. We also consider the treatment of tumours through the inhibition of S1P signalling.
The role of SK1 in cancer transformation
An important observation that suggested the involvement of S1P in cancer was the transformation of NIH3T3 fibroblasts on overexpression of SK1, as demonstrated by their serum-independent proliferation, increased colony formation and growth in vitro and formation of fibrosarcomas when injected into immune compromised mice 5 . These effects were absent for NIH3T3 fibroblasts expressing a dominant-negative kinase-dead G82D SK1 mutant or in the presence of a sphingosine kinase inhibitor, N,N-dimethylsphingosine. Additionally, SK1 activity and foci formation were increased in cells overexpressing a mutant HRAS (V12Ras), which was inhibited by the overexpression of the G82D dominant-negative kinase-dead SK1 mutant 5 . On the basis of these findings, SK1 was defined as an oncogene. However, there is currently no evidence of mutations linked to cancer in SK1. This raises the question of whether SK1 is an oncogene and how it induces the transformation of NIH3T3 fibroblasts. The spontaneous transformation of NIH3T3 cells is perhaps important here, and it is possible that SK1 amplifies their transformation. However, there is substantial evidence that cancer cell lines have increased SK1 expression and are reliant on SK1 for survival and growth (as discussed below). Indeed, cancer cells have been characterized as having a 'non-oncogene addiction' for SK1 (ReF. 6) . However, although SK1 inhibitors induce the apoptosis of cancer cells, other normal cells also undergo cell death in response to SK1 inhibitors. Therefore, whether dependency for SK1 is strictly defined in the context of cancer is also open to debate. Nevertheless, evidence is accumulating to support a role for SK1 in human cancers, such as increased levels of the SK1 mRNA transcript and/or protein in cancers of the stomach 7, 8 , lung 8, 9 , brain 10, 11 , colon 8, 12, 13 and kidney 8 , as well as in non-Hodgkins lymphoma 14 and breast cancer 8, 15, 16 , where SK1 expression was higher in oestrogen receptor-negative (ER -) than in ER + breast tumours 15 . In several of these studies, increased SK1 expression correlated with increased tumour grade and, importantly, reduced patient survival (TABLe 1) .
ABC transporters
A family of proteins that contribute to multi-drug resistance and transport lipids from the inner to the outer leaflet of the plasma membrane.
Translocation
The movement of a protein from one subcellular compartment to another.
Myristoylation and palmitoylation motif
A short sequence of amino acids that become modified by the addition of a lipid group, thereby enabling the membrane-anchoring of the protein.
Interestingly, patient survival prognosis is reduced for patients with breast cancer with high plasminogen activator inhibitor 1 (PAI1) 17 levels and patients with glioma with high PAI1 and epidermal growth factor receptor (EGFR) 18 expression levels: EGF increases PAI1 expression through a SK1-dependent pathway 19 . In addition, analysis of ascites fluid from patients with ovarian cancer shows a significant increase in S1P 20, 21 , whereas a significant decrease in plasma S1P levels was observed in post-operative compared with pre-operative cases 22 . Therefore, extracellular S1P, and that which might be released into the microenvironment of tumours, could have an important role in cancer progression by acting on S1P receptors to promote tumour growth, angiogenesis and metastasis.
'Inside-out' signalling by S1P A functional link has been proposed to exist between S1P receptors and SK1, and this is defined as 'inside-out' signalling 23 (FIG. 2) . It has been proposed that intracellular S1P, produced by SK, is released through transporter proteins (see below) into the extracellular milieu or partitioned into lipid microenvironments in close proximity to S1P receptors. This might allow privileged and efficient binding of S1P to S1P receptors. This model has been used numerous times to explain the behaviour of cancer cells when the S1P signalling system is manipulated (discussed below). However, five criteria should ideally be fulfilled for inside-out signalling to be upheld. The measured response should be ablated by small interfering (siRNA) knock down of SK1, SK1 inhibitors, siRNA knock down of the relevant S1P receptor(s) and siRNA knock down of the S1P transporter. Ideally, S1P release should also be measurable. Additionally, the S1P-specific antibody 24 , which functions as a 'molecular sponge' should ablate the response. The importance of inside-out signalling by S1P in normal compared with tumour cells remains to be defined. In this regard, members of the ABC transporter family, which were originally defined as multidrug transporter proteins, have been implicated in S1P release, for example, ABCC1 (ReF. 25) , ABCA1 (ReF. 26) and ABCG2 (ReF. 27) . However, plasma levels of S1P are the same in ABCC1-or ABCA1-null mice as they are in wild-type mice 28 . This might suggest their lack of involvement in maintaining plasma S1P levels or that a compensatory transport mechanism occurs. Interestingly, protein two of hearts (TOH; also known as SPNS2) has been identified in zebrafish as an S1P transporter 29, 30 . TOH functions upstream of MIL (the orthologue of S1PR 2 ), which is required for heart development. Indeed, mutation of TOH and MIL produces similar phenotypes. It remains to be determined whether the human orthologue of TOH exports S1P from mammalian cells and, if so, whether it is deregulated in cancer.
Spatial signalling by S1P and SK activation The two isoforms of SK differ in their subcellular localization, with SK1 being predominantly cytosolic and SK2 mainly nuclear, thereby creating the potential for distinct functional pools of S1P. However, both isoforms have the potential to move to other subcellular compartments [31] [32] [33] . Many molecules can either activate SK1 acutely or increase its expression chronically. These molecules include agonists of GPCRs and tyrosine kinase receptors, proinflammatory cytokines, immunoglobulin receptors, small GTPases, calcium and protein kinase activators. [31] [32] [33] . SK1 activation involves its translocation to the plasma membrane where it is in close proximity to its substrate, sphingosine. Translocation requires the phosphorylation of SK1 on Ser225, catalysed by ERK1 and ERK2, which also increases SK1 activity (an approximately 14-fold increase in V max ) 34 . Indeed, a Ser225 phosphorylation-deficient SK1 mutant (S225A SK1) fails to translocate to the plasma membrane and produces no enhancement of proliferation or survival when overexpressed in cells 35 . Interestingly, the S225A SK1 mutant inhibits Ras-dependent transformation of NIH3T3 fibroblasts despite exhibiting SK1 activity that is theoretically sufficient to produce transformation. Moreover, artificial targeting of wild-type SK1 or the S225A SK1 mutant to the plasma membrane (by attaching a myristoylation and palmitoylation motif) promotes cellular transformation and increases intracellular S1P
At a glance
• Sphingosine 1-phosphate (S1P) is a biologically active lipid that promotes tumour growth, neovascularization and inflammation. It regulates the growth, survival and migration of mammalian cells through both intracellular and receptor-mediated mechanisms.
• S1P is formed by the sphingosine kinase (SK)-catalysed phosphorylation of sphingosine. There are two isoforms of SK, SK1 and SK2.
• SK1 promotes V12Ras-dependent transformation, and the growth and survival of cancer cells, while inhibiting apoptosis and conferring resistance to γ-irradiation and chemotherapeutic agents.
• No mutations linked with cancer have been identified in SK1. However, cancer cells demonstrate a reliance on this enzyme for cell growth and survival, that is, a non-oncogenic addiction for SK1.
• SK1 expression is increased in several types of human tumours compared with normal tissue and, in some cases, this is correlated with disease progression and reduced patient survival.
• A ceramide-sphingosine-S1P rheostat exists in cells. Ceramide and sphingosine are pro-apoptotic, whereas S1P promotes cell survival. Agents that regulate the interconversion of ceramide-sphingosine-S1P can direct the cell towards either an apoptotic or a survival programme depending on the relative position of the rheostat.
• The sensitivity of cancer cells to chemotherapeutic agents is a function of the activities of SK (which produces S1P) and S1P lyase and S1P phosphatases (which remove S1P).
• S1P stimulates S1P-specific plasma membrane G protein-coupled receptors (S1PR [1] [2] [3] [4] [5] ). S1PR 1 and S1PR 3 generally promote migration and cell survival, whereas S1PR 2 is generally inhibitory for migration.
• S1P receptors crosstalk with receptor tyrosine kinases to regulate tumorigenesis and neovascularization. This includes S1P-dependent transactivation of receptor tyrosine kinases, the formation of functional receptor tyrosine kinase-S1P receptor complexes and the amplification of regulatory loops.
• Solid tumours are often oxygen insufficient and express hypoxia-inducible factors. In this regard, hypoxia increases SK1 and SK2 expression to promote neovascularization of the tumour.
• Anticancer therapeutics in development include S1P-specific neutralizing antibodies (such as ASONEP), SK inhibitors and functional S1P receptor antagonists, which may mitigate the hyperproliferative, migratory and inflammatory components of cancer.
Box 1 | S1P receptors and selected enzymes
Five sphingosine 1-phosphate (S1P)-specific G protein-coupled receptors have been cloned (see the table), termed S1PR 1 -S1PR 5 (ReF. 178) . These differ in their tissue distribution, with S1PR 1 and S1PR 3 being ubiquitously expressed whereas S1PR 4 is largely restricted to lymphoid tissue. Transcript variants of sphingosine kinase 1 (SK1) and SK2 exist. For SK1, transcript variants 2 and 1 have 86 and 14 amino acid amino-terminal extensions compared with transcript variant 3. These variations may contribute to the subcellular localization of the protein but the importance of the transcript variants in cancer, if any, has yet to be realized.
formation and S1P release from cells higher than that observed in cells expressing non-targeted forms of SK1 (ReF. 35) . Additionally, the ERK2-catalysed phosphorylation at Ser225 enhances the membrane affinity and plasma membrane selectivity of SK1, probably through a conformational change that enables Thr54 and Asn89 residues to interact with phosphatidylserine 36 . Indeed, mutation of these residues demonstrated their role in lipid selectivity and membrane targeting 36 . Therefore, the localized production of S1P at the plasma membrane, by virtue of targeted SK1, is the important determinant in transformation (FIG. 3) . Phosphatidic acid activates SK1 in vitro 37 and is produced by phospholipase D, which is implicated in cancer metastasis 38 and is reported to be upstream of SK1 activation 39, 40 . Moreover, phosphatidic acid targets SK1 to the Golgi apparatus, where it seems to regulate cell survival 33, 41, 42 . Taken together, these observations highlight the importance of the spatial regulation of SK1 in cancer.
SK1 activity or localization can also be regulated by various protein-protein interactions. The first interaction to be identified was with tumour necrosis factor (TNF) receptor-associated factor 2 (TRAF2). This adaptor molecule is required for ERK2-catalysed phosphorylation of SK1, and its translocation to the plasma membrane in response to the pro-inflammatory cytokine TNFα is followed by the activation of nuclear factor-κB (NF-κB) and an antiapoptotic effect 43 (for other examples and further details see . Of note is the cell adhesion and signalling molecule PECAM1, which is cytoprotective 44 , upregulated on overexpression of SK1 in endothelial cells and required for their PI3K-AKT-mediated survival 45 . Additionally, aminoacylase 1, identified as a SK1-interacting protein through yeast two-hybrid screening 46 , functions as a tumour suppressor in an animal model of renal cancer 47 . Protein elongation factor 1A (eEF1A), which has been identified as an oncogene 48 , associates with and activates both SK1 and SK2 in vitro 49 . Interestingly, changes in expression of eEF1A were paralleled by changes in expression in cellular SK activity 49 . Most recently, calcium and integrin binding 1 (CIB1; also known as calmyrin) has been shown to interact with SK1 as a calcium-myristoyl 'switch' enabling SK1 translocation to the plasma membrane 50 . However, the relative importance of each of these mechanisms in physiological and pathophysiological conditions remains to be determined.
The role and regulation of SK2 is less well defined. In some cell types, SK2 and SK1 seem to have distinct roles and their differing subcellular localizations could underlie this. For example, SK2 is predominantly localized in the nucleus or at the endoplasmic reticulum 51, 52 . However, phosphorylation of SK2 by protein kinase D results in its export from the nucleus to the cytoplasm 53 .
Recently, a lipid-binding domain (for phosphatidylinositol monophosphates) in SK2 was reported to influence its membrane localization 54 . In contrast to SK1, overexpression of SK2 causes the suppression of cell growth and cell cycle arrest, and these effects require its nuclear localization 52 . Apoptosis that is preceded by the mitochondrial release of cytochrome c and activation of caspase 3 is also seen when SK2 is overexpressed 55 . Indeed, SK2 contains a BH3 domain that sequesters BCL-X L and abrogates its anti-apoptotic function 55 . Therefore, SK2 can be pro-apoptotic 55 . However, other studies support a role for SK2 in promoting survival. For instance, knock down of SK2 in breast or colon cancer cells counters doxorubicin-induced expression of p21 (a cyclin-dependent kinase inhibitor), as well as G2/M cell cycle arrest, and increases doxorubicin-induced apoptosis 56 . In addition, knock down of SK2 in glioblastoma cells inhibits proliferation, and this was more effective than knock down of SK1 (ReF. 11) . EGF activates SK2 (by ERK1-catalysed phosphorylation on Ser351 and Thr578) and is required for EGF-stimulated migration of MDA-MB-453 breast cancer cells 57 . Moreover, the growth of SK2-deficient breast cancer cells in vivo is markedly reduced, and pro-inflammatory macrophages are associated with the tumour 58 . Recently, a new interaction between SK2-S1P and histone deacetylases (HDACs) that exerts epigenetic control in breast cancer cells was reported 59 . In this case, SK2 forms a complex with H3 histone and HDACs. SK2-H3-HDAC repressor complexes were enriched at the promoters of CDKN1A (encoding p21) and FOS (encoding a transcription factor). Activation of SK2 produced S1P, which promotes histone acetylation and binds to HDAC1 and HDAC2 to inhibit their activity, thereby de-repressing CDKN1A and FOS expression. In summary, compartmentalization of S1P by virtue of differing localizations of SK1 and SK2 might enable their differential action on cancer cell function. SK1 and SK2 could function in a redundant manner in normal cells. This is exemplified during development, when knock out of Sk1 in mice is not lethal and produces no noteworthy phenotypic abnormalities 60 , whereas the Sk1;Sk2-double knock out in mice is embyonic lethal 61 . However, redundancy for SK1 is not so apparent in cancer cells, given their addiction to this enzyme and its function in the context of the ceramide-sphingosine-S1P rheostat.
The sphingolipid rheostat and cancer The ceramide-sphingosine-S1P rheostat was proposed early in the genesis of the S1P research field 62 . According to this model, both ceramide and sphingosine are apoptotic, whereas S1P enhances cell survival. Therefore, agents that regulate the interconversion of ceramidesphingosine-S1P can direct the cell towards either an apoptotic or a survival programme depending on the relative position of the rheostat (FIG. 2) . It is well established that ceramide has several intracellular targets that mediate its apoptotic action, including the protein phosphatases PP1 and PP2A 3 , cathepsin D 63 and protein kinase Cζ 64, 65 . By contrast, specific intracellular targets of S1P have remained elusive. Moreover, subsequent release of S1P through membrane transporters might contribute to inside-out protection against apoptosis through the stimulation of S1P receptors. Indeed, exogenous S1P has been shown to regulate the expression of pro-apoptotic and anti-apoptotic proteins. For example, exogenous S1P increases the expression of anti-apoptotic BCL-2 (ReF. 66) and MCL1 (ReF. 67) , while downregulating the pro-apoptotic proteins BAD and BAX 68 . Exogenous S1P also blocks the translocation of BAX to the mitochondria 69 , which is required for the release of mitochondrial cytochrome c and caspase activation 70 . However, the manipulation of SK1 expression also affects the expression of Bcl-2 family members. For example, overexpression of SK1 upregulates BCL-2 and downregulates BIM in endothelial cells 45 . Similarly, overexpression of SK1 inhibits the activation of caspase 3, cytochrome c and SMAC release from mitochondria through the modulation of BIM, BCL-X L and MCL1 in chronic myeloid leukaemia cells 71 , whereas in melanoma cells overexpression and knock down of BCL-2 expression increases and decreases SK1 levels, respectively 72 . There are many examples in which the ceramidesphingosine-S1P rheostat is functional in cancer cell survival, apoptosis and resistance to chemotherapy and radiation in vitro. For example, siRNA knock down of SK1 expression inhibits proliferation and increases the ceramide/S1P ratio and apoptosis of prostate 73, 74 , pancreatic 75 and leukaemia 76 cells. By contrast, the overexpression of SK1 inhibits apoptosis and induces chemoresistance 74, 76, 77 . Indeed, cancer cell lines that are resistant to chemotherapeutic agents have a high expression of SK1, such as prostate cancer cells that are resistant to camptothecin 73, 74 , pancreatic cancer cells resistant to gemcitabine 75 and chronic myeloid leukaemia (CML) cells that are resistant to imatinib 76 . In addition, imatinibsensitive CML cells and daunorubicin-sensitive leukaemia cells have a higher ceramide/S1P ratio than their chemotherapeutic-resistant counterparts 76, 77 . Moreover, the efficacy of chemotherapeutic agents correlates with the extent of SK1 activity inhibition 74, 77 . Interestingly, the treatment of prostate cancer cells with camptothecin upregulates both SK1 and S1P receptors, raising the possibility that resistance to camptothecin could be mediated through inside-out signalling by S1P in these cells 74 .
In vivo evidence also supports a role for SK1 in tumorigenesis, and as a chemotherapeutic 'sensor' 74 . For example, larger tumours were formed when breast and prostate cancer cells overexpressing SK1 were either injected into mammary fat pads 78 or orthotopically implanted 74 into mice compared with those formed by cells expressing endogenous SK1 only. Tumours were also noted to have increased neovascularization 78 , be more resistant to docetaxel 74 and have a reduced ceramide/S1P ratio 74 . In addition, intestinal adenoma size (but not incidence) is reduced in Apc Min/+ ;Sk1-knockout mice 79 . These tumours have increased sphingosine, which was shown to reduce intestinal epithelial cell proliferation, RB phosphorylation and expression of the cell cycle regulator CDC4 in vitro 79 . Therefore, the biologically active potential for sphingosine should not be overlooked. and Apc Min/ + ;S1pr1 +/-bigenic mice, suggesting that S1P can exert its effect through an intracellular action in intestinal adenoma 79 . Given the contrasting roles of ceramide and S1P in cellular programming, there is potential for the therapeutic use of SK inhibitors. Indeed, this has been widely demonstrated in vitro and in vivo (discussed below). For example, SK inhibitors produce sensitization of pancreatic 75 , leukaemia 76 and prostate 80 cancer cells to chemotherapeutic agents. Similarly, SK inhibitors confer sensitization to irradiation, which causes reduced SK activity, increased ceramide and enhanced apoptosis in radiation-sensitive cells but not in radiation-resistant cells 81 . These findings support the hypothesis that the ability of cancer cells to survive is governed by a threshold level of SK1 activity. Therefore, chemotherapeutic agents, γ-radiation and SK1 inhibitors alone might not reduce SK1 activity to below the threshold and so cancer cells survive (through the extracellular and/or intracellular actions of S1P). However, cancer cells undergo apoptosis when SK1 inhibitors and chemotherapy or irradiation are used in combination. S1P receptors, tumour invasion and metastasis As a general principle, S1P stimulates the motility of cancer cells through S1PR 1 or S1PR 3 , when S1PR 1 is coupled to RAC-CDC42 and functions as the predominant pathway and correlates with ERK activation (FIG. 1) . By contrast, S1P can inhibit cancer cell motility through S1PR 2 -dependent regulation of Rho (FIG. 1) . The specific effect of S1P is partly determined by the predominance of the receptor subtypes expressed. For example, S1P stimulates the migration of gastric tumour cells that exclusively express S1PR 3 and inhibits the motility of others that predominantly express S1PR 2 (ReF. 82) . Similarly, the inhibition of melanoma cell migration is through S1PR 2 and involves the inhibition of Rac, activation of Rho, and the subsequent tyrosine phosphory lation of focal adhesion kinase and paxillin 83, 84 . S1P also inhibits the motility of glioblastoma cells through S1PR 2 -mediated RHOA activation and Rac inhibition 85 . Importantly, this was also the case in PTEN-null cells (u87MG glioblastoma and 1321N1 astrocytoma cells). As PTEN has been considered to be indispensible for S1PR 2 -mediated inhibition of somatic cell migration 86 , this might not be the case in cancer cells. By contrast, S1P stimulates the migration of fibrosarcoma cells through a S1PR 1 -RAC1-CDC42-dependent pathway involving the tyrosine phosphorylation of membrane type matrix metalloproteinase 1 (MT1-MMP; also known as MMP14) 87, 88 , , whereas ovarian cancer cell invasion involves S1PR 1 or S1PR 3 and calcium mobilization 89 . However, the response to S1P is cell context dependent. For example, S1P binding to S1PR 2 increases glioma invasiveness by enhancing the expression of the secreted, angiogenic matricellular protein CCN1 (also known as CyR61) 90 . In addition, although S1P stimulation of S1PR 5 blocks glioma proliferation and inhibits ERK activation, this is in contrast to the effect in mouse embryonic stem cells, in which S1P stimulates the ERK pathway through S1PR 5 (ReF. 91) (FIG. 1) . Also, whereas S1P increases the migration of epithelial ovarian cancer cells, it inhibits the migration of human ovarian surface epithelial cells 21 . Although both cell types express S1PR 1 and S1PR 2 , the effects of S1PR 2 predominate in human ovarian surface epithelial cells that also have pre-existing stress fibres that are enhanced by S1P. This contrasts with the effect in epithelial ovarian cancer cells and suggests that preexisting stress fibres might also affect the migratory response to S1P.
There are emerging reports of altered expression 92, 93 or mutation 94 of S1P receptors in cancer. However, the pathophysiological relevance of these observations is not yet clear (TABLe 1) .
Growth factor-S1P signalling interactions There are extensive interactions between the signalling pathways of S1P and growth factors that have been implicated in cancer, such as interactions with EGF, platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) (discussed below), fibroblast growth factor, nerve growth factor and transforming growth factor-β. Examples of mechanisms whereby S1P receptors function in concert with growth factor receptors to regulate processes such as proliferation, migration and angiogenesis include S1P-dependent transactivation of receptor tyrosine kinases, the formation of functional receptor tyrosine kinase-S1P receptor complexes and the amplification of regulatory loops (FIG. 4) . Moreover, multiple mechanisms of signalling interaction can exist for a given agonist, as shown by EGF and PDGF.
S1P and EGF.
In common with several other growth factors, EGF stimulates the expression of SK1 and acutely increases SK1 and/or SK2 activity to induce cell migration in a cell type-specific manner. For example, inside-out signalling in human embryonic kidney cells (HEK293 cells) requires SK1 only 95 , whereas the migration of MDA-MB-453 breast cancer cells involves S1P derived from both SK1 and SK2 (ReF. 57) . Conversely, S1P stimulates EGFR expression in vascular smooth muscle cells 96 . In gastric cancer cells, through a S1PR 2 -and metalloproteinase-dependent mechanism, SIP induces the processing and release of EGF, which activates EGFR 97 , and this process is known as transactivation. Similarly, S1P, through S1PR 3 , transactivates EGFR in MCF-7 breast cancer cells 98 , whereas insulin-like growth factor-binding protein 3-mediated potentiation of EGF-stimulated EGFR activation involves SK1, S1PR 1 and S1PR 3 (ReF. 99) . Additionally, S1P activates ERBB2 (also known as HER2) in gastric cancer cells through an EGFR-and metalloproteinase-dependent mechanism 100 . This might involve the processing and release of EGF, which in turn binds to ERBB2-EGFR heterodimers to stimulate EGFR tyrosine kinase activity and subsequent phosphorylation of EGFR and ERBB2. In the context of S1P signalling, tyrosine-phosphorylated ERBB2 might amplify the EGFR-dependent recruitment of additional signalling components and/or prolong the response. S1P and heregulin. Heregulin, which binds to ERBB3 (also known as HER3) and ERBB4 (also known as HER4), stimulates SK1 activity in A7 melanoma cells. Heregulin-induced migration could involve inside-out signalling by S1P. This is contingent on heregulin inducing the co-localization of a complex that consists of SK1, filamin A (an actin crosslinking protein involved in cell movement) and p21 protein-activated kinase 1 (PAK1) with S1PR 1 in lamellopodia. Filamin A is thought to link SK1 with S1PR 1 , and heregulin fails to stimulate co-localization in filamin A-deficient cells 101 (FIG. 4) . Figure 2 | The ceramide-sphingosine-S1P rheostat, 'inside-out' signalling and cancer cell survival. The relationship of the ceramide (Cer)-sphingosine (Sph)-sphingosine 1-phosphate (S1P) rheostat with cancer cell survival. This occurs through an intracellular signalling mechanism (for example, regulation of BCL-2 family members) and an S1P receptor-dependent mechanism that is downstream of 'inside-out' signalling by S1P. A threshold sphingosine kinase 1 (SK1) activity level seems to govern chemotherapeutic resistance and hormone refractory behaviour. S1PP, S1P phosphatases; S1PR, S1P receptor; SM, sphingomyelinase; SGPL1, S1P lyase. Nature Reviews | Cancer 
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Integrative signalling
The cooperative signalling by two distinct receptor types and/or their downstream signalling components. S1P and PDGF. PDGF-stimulated migration, but not proliferation, of mouse embryonic fibroblasts involves S1PR 1 (ReFS 102,103) . Additionally, S1P, through S1PR 3 , transactivates the PDGFβ receptor (PDGFRβ) in ovarian cancer cells, resulting in the stimulation of ERK and AKT 104 . In smooth muscle cells and mouse embryonic fibroblasts, S1PR 1 and PDGFRβ form a functional signalling complex in which constitutively active S1PR 1 (or S1P-S1PR 1 ) enhances PDGF-stimulated activation of ERK to produce cell migration [105] [106] [107] [108] [109] (FIG. 4) . This represents 'integrative signalling' , which has also been termed 'GPCR jacking' (ReF. 110) . The role of the PDGFRβ-S1PR 1 receptor complex in regulating neovascularization requires further study. However, S1PR 1 is clearly involved in neovascularization as its expression is strongly induced in tumour vessels, and the injection of siRNAs against S1pr1 into tumours suppresses vascular stabilization, angiogenesis and tumour growth 111 .
S1P and VEGF.
There is also crosstalk between S1P and VEGF involving an intracellular S1P regulatory loop in cancer cell lines. VEGF activation of Ras is regulated by a VEGF-induced inhibition of Ras GAP activity. Sphingosine stimulates Ras-GAP activity, whereas S1P blocks this effect. Therefore, VEGF-stimulated activation of SK1 favours the inhibition of Ras-GAP and activation of the Ras-ERK pathway (FIG. 4) . Indeed, inhibition of SK1 reduces VEGF-stimulated ERK activation in bladder, breast, prostate and neuroblastoma cell lines 112 . Interestingly, microvessel outgrowth of aortic rings in culture induced by VEGFA and S1P is increased in tumour suppressor sprouty 4 (also known as SPy4)-knockout mice, in which tumour cells grow faster owing to increased neovascularization 113 . Sprouty 4 reduces Ras-independent VEGFA and S1P-stimulated angiogenic signalling but not Ras-dependent VEGFC signalling. These findings suggest that both VEGFA and S1P can also use overlapping Ras-independent signalling pathways to regulate angiogenesis 113 . S1P and LPA. Amplification loops can regulate S1P signalling in cancer, as exemplified by the functional interaction between lysophosphatidic acid (LPA) and S1P 114 . In several cancer cell types that express the receptor LPAR 1 , LPA markedly increases SK1 expression in an EGFR-dependent manner. However, this is not evident in LPAR 1 -null cancers. LPA is thought to induce a metalloproteinase-dependent release of EGF, which activates EGFR, causing the upregulation of SK1 and the production of S1P. This is then released from the cell to act on S1PR 3 , which stimulates migration and invasion (FIG. 4) . Therefore, SK1 might function as the signalling coordinator of several GPCR and EGFR tyrosine kinase pathways linked in an amplification loop that enhances cancer progression. S1P and oestrogen. The term 'criss-cross transactivation' has been adopted to describe the indirect activation of EGFR by oestrogen in ER + MCF-7 breast cancer cells 98 (FIG. 4) . Oestrogen, through GPR30 (an orphan GPCR) and ERα, acutely activates SK1 that is mediated by ERK1 and ERK2, followed by the release of S1P, stimulation of S1PR 3 , metalloproteinase-mediated EGF release, activation of EGFR and stimulation of the ERK pathway. Indeed, oestradiol induces the release of S1P through ABCC1 and ABCG2 transporter proteins in MCF-7 breast cancer cells 27 . In this scenario, ERK functions both upstream and downstream of SK1. Therefore, S1PR 3 might be a suitable target for therapeutic intervention (using a S1PR 3 -selective antagonist) in ER + breast cancer.
S1P and the development of resistance.
A recent report suggests a relationship exists between SK1 activity and tamoxifen resistance 115 . Enforced expression of SK1 in MCF-7 breast cancer cells increases proliferation and resistance to tamoxifen, whereas siRNA knock down of SK1, but not SK2, restores tamoxifen responsiveness 115 . Notably, tamoxifen resistance has been attributed to a PAK1-catalysed phosphorylation of Ser305 and ERKcatalysed phosphorylation of Ser118 in ERα 116 , resulting in ligand-independent activity. The requirement of SK1-S1P for ERK and PAK1 to induce tamoxifen resistance needs formal investigation.
There might also be a relationship between SK1 and the acquisition of androgen independence. Indeed, chronic androgen deprivation of androgen-sensitive prostate cancer cells (which mimics androgen ablation therapy) results in the acquisition of androgen independence and correlates with increased SK1 expression and activity 117 . The development of androgen independence can be prevented by the inhibition of the PI3K-AKT pathway or SK1 (ReF. 117) . Interestingly, AKT activity is higher in androgen-independent prostate cancer compared with androgen-sensitive tumours 118 . Moreover, AKT phosphorylates the androgen receptor on Ser210 and Ser790 (ReF. 119) resulting in its transactivation and translocation to the nucleus where it activates the expression of genes that are involved in proliferation in the absence of androgen. Therefore, increased SK1 expression on androgen deprivation might promote cell survival (through a decrease in the ceramide/S1P ratio) and, through inside-out signalling, S1P receptor-driven AKT phosphorylation of the androgen receptor and proliferation. However, this model requires formal investigation.
Hypoxia and S1P signalling Sustained hypoxia increases SK1 and SK2 expression in proliferating human pulmonary smooth muscle cells 120 . Indeed, the SK1 promoter has two hypoxiainducible factor-responsive elements (HREs) and both hypoxic-inducible factors HIF1α and HIF2α have been implicated in the transcriptional regulation of SK1 (ReFS 121, 122) . Hypoxia promotes endothelial cell migration 121 and increases S1P production and release from glioma cells 122 . Therefore, oxygen-insufficient solid tumours, which express HIFs, might be protected from hypoxia-induced stress owing to increased SK1 expression: that is, localized S1P released from tumour cells might stimulate endothelial cells, fibroblasts and smooth muscle cells resulting in increased neovascularization, thereby correcting the oxygen insufficiency to the tumour with SK1 functioning as a responder to the HIF1α and HIF2α sensors of oxygen insufficiency.
Interestingly, SK1 might also modulate the sensitivity of cancer cells to oxygen deprivation by regulating the levels of HIF1α. SK1 is activated under hypoxic conditions by a reactive oxygen speciesdependent mechanism and increases the expression of HIF1α in glioma, prostate and breast cancer cell lines 123 . However, SK1 inhibition or knock down of SK1 expression lowers HIF1α levels. Additionally, HIF1α is stabilized by a hypoxia-induced and SK1-dependent activation of AKT 123 . SK2 is also sensitive to hypoxic conditions. In this regard, hypoxia protects lung adenocarcinoma cells from etoposide-induced death by increasing the expression of SK2, the release of S1P, and inside-out signalling through S1PR 1 and S1PR 3 (ReF. 124) .
Autophagy
Autophagy is a process that can mediate either cell survival or a death response. It can be initiated in response to oxidant stress, nutrient insufficiency or endoplasmic reticulum stress, for example. When mediating cell survival, autophagy confers resistance to chemotherapy, radiotherapy and immunotherapy 125 . Recently, nutrient starvation of breast cancer cells was shown to activate SK1 and autophagy-mediated survival, which could also be induced by SK1 overexpression 126 . This correlated with a relatively small increase in beclin 1 (BECN1) expression, whereas ceramide substantially increased the expression of BECN1 and induced an autophagy-mediated death response. In this regard, inhibitors of SK1 and SK2 (ReF. 8) or of SK2 alone 127 induced autophagic cell death in several tumour lines Figure 4 | Interaction between S1P and eGFr, and VeGFr2 and PDGFrβ. a | A sphingosine kinase 1 (SK1) -filamin Ap21 protein-activated kinase 1 (PAK1) complex is required for SK1-dependent actin polymerization and the close proximity association of SK1 with sphingosine 1-phosphate receptor 1 (S1PR 1 ), thereby facilitating S1P release to initiate S1PR 1 -dependent motility. b | A PDGFRβ-S1PR 1 receptor complex regulates platelet-derived growth factor (PDGF)-stimulated migration of smooth muscle cells and fibroblasts, and has a possible role in the neovascularization of tumours. S1PR 1 is constitutively active in this complex. c | SK1-and S1P-dependent regulation of Ras -GAP, and the promotion of vascular endothelial growth factor (VEGF)-induced Ras-ERK1-ERK2 signalling in endothelial cells is required for the neovascularization of tumours. d | The lysophosphatidic acid (LPA)-dependent transactivation of epidermal growth factor receptor (EGFR) with upregulation of SK1 expression, subsequent S1P release and S1PR 3 receptor activation promotes migration and invasiveness. e | SK1 and subsequently released S1P stimulates S1PR 3 to transactivate EGFR and promote tumorigenesis. β-arr, β-arrestin; GAB1, growth factor receptor binding protein associated binder 1; MMP, metalloproteinase; P, phosphorylation; PDGFR, PDGF receptor; PKC, protein kinase C; Sph, sphingosine.
in vitro and reduced tumour growth in vivo 128, 129 , presumably owing to a shift in the ceramide/S1P ratio in favour of ceramide. Additionally, exogenous S1P induced autophagy-mediated survival in nutrient-deprived prostate cells through S1PR 5 -mediated inactivation of mTOR (which can integrate PI3K and phosphatidic acid signals), resulting in the loss of autophagy suppression 130 . One might expect the SK1-induced autophagic survival response to be transient in vivo because the ensuing hypoxia also induces SK1 expression, resulting in neovascularization and a resupply of nutrients and oxygen. The role of SK in terms of regulating autophagy-mediated survival in cancer is an area that requires further research, especially given the important therapeutic possibilities.
S1PP, SGPL1, cancer and inflammation
To date, SK has largely been the focus of research relating to S1P in cancer. However, evidence is emerging relating to the enzymes that remove S1P -S1P phosphatases and SGPL1. For example, the level of SGPL1 mRNA expression is reduced in intestinal cancer 131 and metastatic tumours 132 . Conversely, others have reported increased levels of SGPL1 mRNA in ovarian cancer 133 and in chemotherapeutic-resistant ovarian tumours 134 . Therefore, the role of SGPL1 in tumorigenesis and disease progression remains to be defined (TABLe 1) . However, the sensitivity of lung cancer cells to cisplatin and doxorubicin is increased by overexpression of SGPL1 through a mechanism that principally involves p38 MAPK and to a lesser extent juN N-terminal kinase (jNK) 135 . Additionally, SGPL1 regulates apoptosis in response to cellular stress and in a manner independent of ceramide but requiring SGPL1 activity, p38 MAPK, p53, p53-inducible death domain protein and caspase 2 (ReF. 131) . Indeed, SGPL1 expression seems to be linked to the constitutive activation of p38 MAPK. SGPL1 is also downregulated in adenoma lesions of the Apc Min/+ mouse model, in which the higher levels of sphingosine were suggested to exert selective pressure to increase SK1 expression and thereby convert sphingosine to S1P to promote cell survival 131 . Additionally, SK1 expression is increased in azoxymethane-induced mouse colon carcinomas, but not in adenomas, suggesting that SK1 overexpression is a late event in intestinal tumorigenesis 136 . At present, evidence of a role for S1P phosphatases in cancer is limited. However, siRNA knock down of S1PP1 confers resistance to chemotherapy and enhances both intracellular and extracellular S1P levels 137 . By contrast, S1PP2 is reported to have a pro-inflammatory role, being selectively upregulated in response to TNFα or lipopolysaccharide in endothelial cells and required for the transcription of the gene encoding interleukin-1β (IL-1β) 138 . This is somewhat unexpected given the emerging association between inflammation and cancer and the wealth of evidence to support SK1-S1P in inflammation. For example, inflammatory mediators such as TNFα stimulate SK activity 43 , and S1P stimulates the expression of cyclooxygenase 2 (COX2) and the production of prostaglandin E2 (PGE 2 ) 139 , both of which are implicated in colon cancer tumorigenesis. Knock down of SK1 expression reduces the expression of COX2 and PGE 2 (ReF. 136) . Importantly, in mouse models of colitis and colon cancer, SK inhibitors reduce inflammation 140 , which is also less severe in Sk1 -/-mice 13, 141 : these mice lack colonic COX2 induction 141 . With continued research in the area of inflammation and cancer, the subtleties of S1P signalling should be deciphered and could provide new opportunities for the development of targeted therapeutics.
S1P pathway therapeutics
Strategies that have been adopted to limit the effects of S1P signalling in cancer include the sequestration of released S1P, inhibition of SK1 and/or SK2 and targeting of specific S1P receptors. Each of these approaches has been successful in vitro and/or in vivo, as detailed in TABLe 2 and briefly summarized below. S1P-specific antibodies. S1P-specific antibodies function as molecular sponges to deplete S1P from blood and other compartments. An S1P-specific monoclonal antibody reduced tumour progression and, in some cases, eliminated tumours in mouse xenograft and allograft models 24 . Anti-angiogenic and anti-tumorigenic effects were observed in vivo and S1P-stimulated proliferation, release of pro-angiogenic factors (VEGF, IL-6 and IL-8) and protection from apoptosis were inhibited for tumour cells in vitro. Two monoclonal S1P-specific antibodies, LT1002 and a humanized form of LT1009, have high specificity for S1P and do not cross react with other structurally related lipids 142 . LT1009 has been formulated for Phase 1 clinical trials in cancer as ASONEP (LPath, Inc.) and for age-related macular degeneration as iSONEP (LPath, Inc.).
SK inhibitors.
There is intense activity to identify and develop SK1 inhibitors. Notably, these might exert their effects not only by the reduction in S1P formation and/or release but also by knock-on effects of sphingosine, ceramide and ceramide metabolites 3 .
The sphingosine analogues DMS (N,N-dimethylsphingosine) and sphinganine (d,l-threo-dihydrosphingosine) have been widely used as pharmacological inhibitors of SK. However, these compounds, which function competitively, are not isoform specific. Importantly, despite showing efficacy in cancer models 143, 144 , they cause haemolysis and are hepatotoxic 145 , and they inhibit protein kinase C 146 and ceramide kinase 147 , and activate sphingosine-dependent protein kinase 148 . Sphingosine also activates PI3K 149 and casein kinase 2 (ReF. 150) and these sphingosine analogues may have similar effects. Safingol (l-threo-dihydrosphingosine), which inhibits SK1, but is also a protein kinase C inhibitor 151 , has been assessed in Phase I clinical trials. A genistein derivative, phenoxodiol, which reduces the activation of SK 152 is in clinical trials for ovarian and prostate cancers. However, the effect of phenoxodiol on SK is indirect, mediated through an altered ubiquinone/ubiquinol/NADH ratio owing to the inhibition of a cancer-specific cell surface NADH oxidase 
Stage of development Comments
Sequestration of S1P S1P-specific antibody Depletion of extracellular S1P
In vitro
Reduced proliferation, reduced inhibition of apoptosis, reduced release of pro-angiogenic factors (VEGF and FGF) 24, 142 In vivo Reduced angiogenesis, tumour growth and metastasis in breast, ovarian, lung and melanoma models; reduced numbers of circulating lymphocytes 24, 142 Clinical trial Phase I: ASONEP is the systemic formulation for cancer (iSONEP is the ocular formulation for acute macular degeneration)
Inhibition of SK activity DMS (N,Ndimethylsphingosine) and sphinganine (d,l-threodihydrosphingosine)
SK1 and SK2
In vitro • K i ~5-10 mM, sphingosine competitive inhibition 181, 182 • Inhibits PKC and ceramide kinase; activates sphingosine-dependent kinase.
May activate PI3K and casein kinase 2 (ReFS 146-150) • Inhibition of growth, induction of apoptosis, sensitization to radiation and chemotherapeutics 78, 143, [183] [184] [185] [186] In vivo Inhibition and regression of gastric and lung tumour growth, and reduced metastasis. Drug is haemolytic and hepatotoxic 143, 145, 184 SK1-I (BML-258, • Inhibition of growth and survival, induction of apoptosis in leukaemia 154 and glioblastoma cells 155 . More potent against AML leukaemic blasts than mononuclear leukocytes from healthy donors 154 
In vivo
• Inhibition of AML xenograft growth • Induced apoptosis in both chemoresistant and chemosensitive HL-60 cell and CML cells 71, 189 S-15183a and S-15183b (natural products from culture broth of a fungus, Zopfiella inermis; SANK 15183) SK (isoform specificity not determined)
In vitro
Reduced S1P formation in platelets 160 Amidine-based range of sphingosine analogues
SK1 and SK2
In vitro • K i in mM range, competitive with sphingosine • Reduced S1P formation and inhibition of proliferation in vascular smooth muscle cells 190 (ECTO-NOX) 153 . Moreover, phenoxodiol also downregulates anti-apoptotic proteins, induces AKT downregulation and inhibits topoisomerase II.
Various short chain sphingosine and dihydrosphingosine analogues have been synthesized and assessed as SK inhibitors. Subsequently, SK1-I (BML-258; (2R,3S,4E)-
, a water-soluble sphingosine analogue was synthesized 154 . This is the first isoform-selective inhibitor to be identified, and is specific for SK1. Additionally, it fails to inhibit other non-related kinases (TABLe 2) and is efficacious both in vitro and in vivo. Importantly, SK1I enhanced survival in an orthotopic intracranial tumour model 155 . Other sphingosine analogues with increased potency compared with DMS have been synthesized but their specificity for SK compared with other kinases and efficacy in vitro and in vivo is yet to be established 156, 157 . The first non-lipid SK inhibitors were identified from a medium-throughput screen 8 . Of these, SKi (SKI-II; 2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole)) is non-competitive with ATP, which should result in improved selectivity. Indeed, SKi was shown not to inhibit the other kinases tested 8 . SKi (and other compounds identified in the same study) reduced S1P, inhibited proliferation and induced apoptosis in various cancer cell lines 8 . Subsequently, SKi was shown to be orally biologically available and to have both antitumour 128 and anti-inflammatory activity in vivo 140 . Most recently, a SK2-selective inhibitor, ABC294640 (3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide) has been identified 127 . This compound also inhibits tumour proliferation and migration in vitro and is an effective orally biologically available anticancer agent in vivo 127, 129 , in which it also induces autophagic cell death 129 . Several natural products, B-5354c 158 F-12509A 159 and S-15183a,b 160 , have been isolated and shown to inhibit SK in vitro. However, the specificity of these compounds is unclear. Nevertheless, they affect the ceramide/S1P ratio in vitro, and B-5354c reduces tumour growth in vivo (TABLe 2) . S1P receptor agents. Several S1P receptor-selective reagents are available 161 . In particular, antagonists to S1PR 1 and S1PR 3 (TABLe 2) could be relevant given the roles of these receptors in cell proliferation, migration, invasion and angiogenesis and interaction with growth factor receptor signalling (as discussed above). However, the potential for these reagents in anticancer therapeutics has yet to be established. Moreover, the ubiquitous distribution of S1PR 1 and its importance in vascular permeability and lymphocyte migration are important considerations.
The immunosuppressant FTy720 (fingolimod) is a sphingosine analogue that has anticancer effects (TABLe 2) . It is taken up by cells, phosphorylated to FTy720-phosphate by SK2 (ReF. 162) and then released. FTy720-phosphate binds to S1P receptors (S1PR 1 , S1PR 3 , S1PR 4 and S1PR 5 ) 163 and produces rapid polyubiquitylation, endocytosis and proteasomal degradation of S1PR 1 (ReF. 164) in T lymphocytes, thereby preventing their egress from the lymph 165 . Importantly, FTy720 has biological actions that are distinct from those of FTy720-phosphate. For example, FTy720-phosphate inhibits autotaxin 166 whereas FTy720 inhibits phospholipase A 2 (ReF. 167 ), SGPL1 168 , SK1 (ReF. 169 ) and ceramide synthase 170, 171 and activates PP2A and PP2A-like phosphatases 172, 173 . Examples of the efficacy of FTy720 in vivo are numerous (TABLe 2) with cancer cell-selective apoptosis 174 , reduced tumour vascularization and angiogenesis 175 , and reduced plasma LPA levels 166 . FTy720, but not FTy720-phosphate, is antiproliferative in breast and colon cancer cells in vitro, indicating an S1P receptor-independent effect 176 . , SGPL1 168 and ceramide synthase 170, 171 . Activation of PP2A 172, 173 • Growth arrest and apoptosis of various cancer cell lines 176, [193] [194] [195] [196] • Inhibition of ERK1, ERK2 and Akt phosphorylation. Activation of caspases, JNK and PKCd. Increased ROS production 176, 193, 195, 197 • Phosphorylated by SK2 (ReFS 162, 198) • FTY720-phosphate is agonist of S1PR 1, S1PR 3 , S1PR 4 and S1PR 5 (ReF. 163) In vivo • Growth inhibition in various mouse tumour models; inhibition of tumour vascularization and angiogenesis 194, 196, [199] [200] [201] • Reduced plasma LPA levels 166 AML, acute mylogenous leukaemia; CamKIIb, calcium/calmodulin-dependent protein kinase 2b; CDK2, cyclin-dependent kinase 2; CML, chronic myelogenous leukaemia; EGFR, epidermal growth factor receptor; FGF, fibroblast growth factor; IKKb, inhibitor of nuclear factor kappa B kinase beta subunit; LPA, lysophosphatidic acid; PKC, protein kinase C; PP2A, protein phosphatase 2A; ROS, reactive oxygen species; S1P, sphingosine 1-phosphate; SGPL1, S1P lyase; SK, sphingosine kinase; VEGF, vascular endothelial growth factor.
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• Chemotherapeutic resistance • Tamoxifen resistance • Androgen independence By contrast, FTy720 reduced angiogenesis in an in vitro spheroid model and this was mimicked by the S1PR 1 -selective agonist SEW2871, indicating that this effect of FTy720 is probably through FTy720-phosphate and is an S1PR 1 -dependent effect 177 . Therefore, the mechanism underlying the observed anticancer actions of FTy720 are likely to be complex.
Conclusion and future perspectives
There is considerable information concerning the role of S1P receptors in cancer, both in terms of regulating cancer cell motility and proliferation through the interaction with growth factor receptors, and in terms of regulating angiogenesis (FIG. 5) . The release of S1P from cancer cells might predominantly function to bind to S1P receptors on other cells in the vasculature to promote angiogenesis. However, released S1P might also function in an autocrine manner to protect cancer cells against apoptosis and to promote their growth. SK1 expression and activity is increased in several tumour types, correlates with reduced life expectancy and contributes to chemotherapeutic resistance as well as, possibly, to the development of hormone refractory tumours. Therefore, therapies that shift the ceramide-sphingosine-S1P rheostat towards ceramide and that decrease SK1 activity below its threshold for cancer cell survival are the way forward. An unmet challenge is to selectively induce cancer cells to become devoid of SK1 activity.
The discrimination of the role of SK1 from SK2 and further understanding of the spatial aspects of intracellular S1P signalling as it relates to the subcellular compartmentalization will be key to identifying new therapeutic options.
Clearly, on reviewing this burgeoning area of research, one can say with confidence that targeting the S1P pathway for therapeutic development should offer new and exciting strategies to tackle cancer effectively. Sphingosine 1-phosphate (S1P) has multiple effects in cancer, including transformation, growth, survival, motility, neovascularization, hormone resistance and inflammation. COX, cyclooxygenase; PGE 2 , prostaglandin E 2 .
